Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis.
Melanoma Literature
Publication date: May 18, 2022 The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K-mutated melanoma is limited and transient. Resistance largely occurs ... Read more